DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?

Quest Diagnostics (DGX) is anticipated to report strong Q2 2025 results, with consensus estimates projecting a 13.4% year-over-year revenue increase to $2.72 billion and a 9.4% rise in EPS to $2.57, extending its consistent trend of earnings beats. This positive outlook is driven by robust demand across its Advanced Diagnostics portfolio, expanded health plan network access, strategic acquisitions contributing significantly to revenue growth, and operational efficiencies from automation and AI. The company's positive Earnings ESP further indicates a high probability of exceeding current estimates.

Analysis

Quest Diagnostics (DGX) is positioned for a strong second-quarter 2025 earnings report, with consensus estimates pointing to a significant 13.4% year-over-year revenue increase to $2.72 billion and a 9.4% rise in EPS to $2.57. This outlook is supported by a consistent history of earnings beats, averaging a 2.03% surprise over the trailing four quarters. Growth is multifaceted, driven primarily by the core Diagnostics Information Services (DIS) business, where the Advanced Diagnostics portfolio—including tests for women's health, Alzheimer's risk, and minimal residual disease—is a key catalyst. Inorganic growth is also a substantial contributor, with eight acquisitions from the prior year expected to account for 5.8 percentage points of the forecasted 13.5% growth in DIS revenue. Furthermore, top-line expansion is being amplified by expanded health plan access with Elevance Health and inclusion in the Optum Health preferred lab network. Operationally, the company's "Invigorate" program is on track for its 3% annual cost savings target, complemented by technology deployments in automation and AI, which are expected to drive a 13.6% year-over-year increase in non-GAAP operating income. The positive Earnings ESP of +0.67% combined with a Zacks Rank #3 further strengthens the statistical probability of the company surpassing current earnings estimates.

Key Decisions for Investors

• Given the multiple growth drivers, positive estimate revisions, and a quantitative model indicating a high likelihood of an earnings beat, investors may consider maintaining or building a long position ahead of the Q2 2025 report.
• During the upcoming earnings call, investors should scrutinize the performance of the Advanced Diagnostics portfolio and the specific revenue contribution from recent acquisitions to validate the growth thesis.
• Monitor management's commentary on the progress of the 'Invigorate' cost-saving program and the tangible impact of technology partnerships on operating margins, as these are critical for assessing long-term earnings power and profitability.